ArticleACS omega2025
Synthesis of a New Benzylated Derivative of Rutin and Study of Its Cosmetic Applications.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Metabolism-Guided Framework for Selecting Structural Modification or Nano-Delivery Strategies for Oral Rutin.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to obtain a derivative of rutin that has biological activities for cosmetic applications. The benzylated derivative of rutin was prepared through a substitution reaction of the hydrogens and aromatic rings of rutin by benzylation with benzyl bromide, and the product of this synthesis was encoded as RuDiOBn. The structural elucidation of the compound was performed using NMR and LC-MS/MS. Assays were performed to examine antioxidant (DPPH, ABTS, and cellular antioxidant) content, enzyme and glycation inhibition, cytotoxicity, proliferation, and inhibition of collagen production. In the in vitro glycation assay, RuDiOBn inhibited the formation of advanced glycation end products in collagen via the glyoxal pathway, with an IC
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.